1 / 15

Joint Arthritis & Drug Safety and Risk Management Advisory Committee February 18, 2005

Joint Arthritis & Drug Safety and Risk Management Advisory Committee February 18, 2005 Sharon Hertz, M.D. Deputy Director Division of Anti-Inflammatory, Analgesic, and Ophthalmologic Drug Products. Reason we are here. Pain drugs are critically important Cox-2 selectives extensively studied

jaime-carpenter
Télécharger la présentation

Joint Arthritis & Drug Safety and Risk Management Advisory Committee February 18, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Joint Arthritis & Drug Safety and Risk Management Advisory Committee February 18, 2005 Sharon Hertz, M.D. Deputy Director Division of Anti-Inflammatory, Analgesic, and Ophthalmologic Drug Products

  2. Reason we are here • Pain drugs are critically important • Cox-2 selectives extensively studied • Over time studies have revealed new potential uses and risks • Raise questions about whether the CV risk is • Limited to individual products • Applies to all Cox-2 selective drugs • Extends to non-selective NSAIDS

  3. Safety Assessment NDA Outcome Studies Celebrex 9600 CLASS 7900 Vioxx 5400 VIGOR 8000 Bextra 5500 ---- Etoricoxib* 5800 EDGE 7100 Lumiracoxib* 7000 TARGET 18,000 *Etoricoxib, lumiracoxib, and parecoxib not approved in U.S.

  4. Cox-2 Inhibitors and CV Risk Some studies appear to show an increased risk of CV events, but the findings are not consistent across the COX-2 selective NSAIDs. There may be similar risk with some of the non-selective NSAIDs. Clinical trial data are also not consistent and suggest this may be more of an effect with some than others.

  5. Cox-2 Inhibitors and CV Risk • Story of conflicting data • Short term vs. long term vs. epi studies • Populations differ • Comparators differ • Similar study designs show different results • More than one mechanism possible • Little known about non-selective NSAIDs • Data has been inconsistent • Multiple products/generics will make study difficult

  6. Effect of ASA in Cox-2 Studies • Conflicting data - ASA appears to mitigate risk some studies, but not all. • Unclear effect ASA use has on GI benefit of relative Cox-2 selectivity

  7. Where are we today? • Conflicting data and many questions • Must move forward • Determine role of approved products on market today • Assess need for more studies • What studies would be most helpful

  8. Question 1, 2, 3 Do the available data support a conclusion that celecoxib, rofecoxib and valdecoxib significantly increase the risk of cardiovascular events? Does the overall risk versus benefit profile for each of these support marketing in the US? If yes, please describe the patient population(s) in which the potential benefits of celecoxib outweigh the potential risks and what actions you recommend that FDA consider implementing to ensure safe use.

  9. Question 4 If the available data support a conclusion that one or more COX-2 selective agents increase the risk of cardiovascular events, please comment on the role, if any, of concomitant use of low-dose aspirin in reducing cardiovascular risk in patients treated with COX-2 selective NSAIDs.

  10. Question 5 (1) What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential cardiovascular risk of celecoxib, rofecoxib, and valdecoxib? What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential benefits (e.g., reduced gastrointestinal risk) of celecoxib, rofecoxib, and valdecoxib?

  11. Question 6 Do you recommend that the labeling for these products include information regarding the absence of long-term controlled clinical trial data to assess the potential cardiovascular effects of these drugs? If so, please describe how you recommend that information be conveyed (e.g., warning, precaution).

  12. Question 7 What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential cardiovascular risk of the non-selective NSAIDs?

  13. Question 8 (1) With regard to evaluation of cardiovascular risk, what studies do you recommend as essential to be completed and reviewed prior to approval of new NSAIDs? With regard to the evaluation of the potential benefits (e.g., reduced gastrointestinal risk), what studies do you recommend as essential to be completed and reviewed prior to approval of new NSAIDs?

  14. Question 9 (1) If the pre-approval studies recommended as essential in question 8 do not demonstrate an increased risk of cardiovascular events for a new NSAID, please comment on how FDA should handle the issue of cardiovascular risk in labeling. For example, would the absence of a cardiovascular risk signal in the pre-approval database preclude the need for any warnings or precautions in the labeling for the new product?

  15. Question 9 (2) Alternatively, should all future NSAIDs carry a “class” warning or precaution about cardiovascular risk even in the absence of a signal of increased risk in the pre-approval database? If yes, please describe your recommendations for the “class” labeling regarding cardiovascular risk with particular attention to whether you recommend it apply to all NSAIDs or only COX-2 selective NSAIDs.

More Related